Weekly Vitals: St. Jude Down in Q1, FDA Rips European Approval System, and More

St. Jude reported an unsurprising 9% drop in Q1 earnings this week attributed to weak heart-rhythm sales in the wake of image woes and skepticism following the Riata lead recall in December. Also this week, the Minneapolis Star Tribune ran an interesting story highlighting FDA's view of Europe's medical device approval process while medical device hacking once again nabbed headlines. Read these and other top stories of the week in our weekly roundup below.